John Kastelein

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Rensing Katrijn L; Kastelein John J P; Twickler Marcel
Is insulin the preferred compound in lowering glucose levels in patients after a myocardial infarction?
Oosterveer Daniëlla M; Versmissen Jorie; Yazdanpanah Mojgan; van der Net Jeroen B; Defesche Joep C; Kastelein John J P; Sijbrands Eric J G
5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia.
Duivenvoorden Raphaël; de Groot Eric; Stroes Erik S G; Kastelein John J P
Surrogate markers in clinical trials--challenges and opportunities.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of John Kastelein (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Rensing Katrijn L; Kastelein John J P; Twickler Marcel
Is insulin the preferred compound in lowering glucose levels in patients after a myocardial infarction?
Archives of internal medicine 2009;169(17):1636-7; author reply 1637-8.
2009: Oosterveer Daniëlla M; Versmissen Jorie; Yazdanpanah Mojgan; van der Net Jeroen B; Defesche Joep C; Kastelein John J P; Sijbrands Eric J G
5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia.
Atherosclerosis 2009;206(1):223-7.
2009: Duivenvoorden Raphaël; de Groot Eric; Stroes Erik S G; Kastelein John J P
Surrogate markers in clinical trials--challenges and opportunities.
Atherosclerosis 2009;206(1):8-16.
2009: Arsenault Benoit J; Lemieux Isabelle; Després Jean-Pierre; Gagnon Pascale; Wareham Nicholas J; Stroes Erik S G; Kastelein John J P; Khaw Kay-Tee; Boekholdt S Matthijs
HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.
Atherosclerosis 2009;206(1):276-81.
2009: Faergeman Ole; Holme Ingar; Fayyad Rana; Bhatia Sonal; Grundy Scott M; Kastelein John J P; LaRosa John C; Larsen Mogens Lytken; Lindahl Christina; Olsson Anders G; Tikkanen Matti J; Waters David D; Pedersen Terje R;
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease.
The American journal of cardiology 2009;104(4):459-63.
2009: Holme Ingar; Strandberg Timo E; Faergeman Ole; Kastelein John J P; Olsson Anders G; Tikkanen Matti J; Larsen Mogens Lytken; Lindahl Christina; Pedersen Terje R;
Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL).
Atherosclerosis 2009;205(2):522-7.
2009: van Zaane Bregje; Reuwer Anne Q; Büller Harry R; Kastelein John J P; Gerdes Victor E A; Twickler Marcel Th B
Hormones and cardiovascular disease: a shift in paradigm with clinical consequences?
Seminars in thrombosis and hemostasis 2009;35(5):478-87.
2009: Stein Evan A; Stroes Erik S G; Steiner George; Buckley Brendan M; Capponi Alessandro M; Burgess Tracy; Niesor Eric J; Kallend David; Kastelein John J P
Safety and tolerability of dalcetrapib.
The American journal of cardiology 2009;104(1):82-91.
2009: Duivenvoorden Raphaël; de Groot Eric; Afzali Hamid; Vanbavel Ed T; de Boer Onno J; Laméris Johan S; Fayad Zahi A; Stroes Erik S G; Kastelein John J P; Nederveen Aart J
Comparison of in vivo carotid 3.0-T magnetic resonance to B-mode ultrasound imaging and histology in a porcine model.
JACC. Cardiovascular imaging 2009;2(6):744-50.
2009: Reuwer Anne Q; Nieuwland Rienk; Fernandez Isabelle; Goffin Vincent; van Tiel Claudia M; Schaap Marianne C L; Berckmans René J; Kastelein John J P; Twickler Marcel Th B
Prolactin does not affect human platelet aggregation or secretion.
Thrombosis and haemostasis 2009;101(6):1119-27.
2009: Bisoendial Radjesh J; Birjmohun Rakesh S; Akdim Fatima; van 't Veer Cornelis; Spek C Arnold; Hartman Daniel; de Groot Els R; Bankaitis-Davis Danute M; Kastelein John J P; Stroes Erik S G
C-reactive protein elicits white blood cell activation in humans.
The American journal of medicine 2009;122(6):582.e1-9.
2009: Semb Anne G; Ueland Thor; Aukrust Pål; Wareham Nicholas J; Luben Robert; Gullestad Lars; Kastelein John J P; Khaw Kay-Tee; Boekholdt S Matthijs
Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(6):975-80.
2009: Holme Ingar; Szarek Michael; Cater Nilo B; Faergeman Ole; Kastelein John J P; Olsson Anders G; Tikkanen Matti J; Larsen Mogens Lytken; Lindahl Christina; Pedersen Terje R;
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2009;16(3):315-20.
2009: Beigneux Anne P; Franssen Remco; Bensadoun André; Gin Peter; Melford Kristan; Peter Jorge; Walzem Rosemary L; Weinstein Michael M; Davies Brandon S J; Kuivenhoven Jan A; Kastelein John J P; Fong Loren G; Dallinga-Thie Geesje M; Young Stephen G
Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(6):956-62.
2009: Koeijvoets Kristel C M C; van der Net Jeroen B; Dallinga-Thie Geesje M; Steyerberg Ewout W; Mensink Ronald P; Kastelein John J P; Sijbrands Eric J G; Plat Jogchum
ABCG8 gene polymorphisms, plasma cholesterol concentrations, and risk of cardiovascular disease in familial hypercholesterolemia.
Atherosclerosis 2009;204(2):453-8.
2009: Strandberg Timo E; Holme Ingar; Faergeman Ole; Kastelein John J P; Lindahl Christina; Larsen Mogens Lytken; Olsson Anders G; Pedersen Terje R; Tikkanen Matti J;
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
The American journal of cardiology 2009;103(10):1381-5.
2009: Henneman Peter; van der Sman-de Beer Femke; Moghaddam Payman Hanifi; Huijts Petra; Stalenhoef Anton F H; Kastelein John J P; van Duijn Cornelia M; Havekes Louis M; Frants Rune R; van Dijk Ko Willems; Smelt Augustinus H M
The expression of type III hyperlipoproteinemia: involvement of lipolysis genes.
European journal of human genetics : EJHG 2009;17(5):620-8.
2009: Glynn Robert J; Danielson Eleanor; Fonseca Francisco A H; Genest Jacques; Gotto Antonio M; Kastelein John J P; Koenig Wolfgang; Libby Peter; Lorenzatti Alberto J; MacFadyen Jean G; Nordestgaard Børge G; Shepherd James; Willerson James T; Ridker Paul M
A randomized trial of rosuvastatin in the prevention of venous thromboembolism.
The New England journal of medicine 2009;360(18):1851-61.
2009: van der Net Jeroen B; Versmissen Jorie; Oosterveer Daniëlla M; Defesche Joep C; Yazdanpanah Mojgan; Aouizerat Bradley E; Steyerberg Ewout W; Malloy Mary J; Pullinger Clive R; Kane John P; Kastelein John J P; Sijbrands Eric J G
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and coronary heart disease risk in familial hypercholesterolemia.
Atherosclerosis 2009;203(2):472-8.
2009: Meuwese Marijn C; de Groot Eric; Duivenvoorden Raphaël; Trip Mieke D; Ose Leiv; Maritz Frans J; Basart Dick C G; Kastelein John J P; Habib Rafik; Davidson Michael H; Zwinderman Aeilko H; Schwocho Lee R; Stein Evan A;
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.
JAMA : the journal of the American Medical Association 2009;301(11):1131-9.
2009: Tikkanen Matti J; Holme Ingar; Cater Nilo B; Szarek Michael; Faergeman Ole; Kastelein John J P; Olsson Anders G; Larsen Mogens Lytken; Lindahl Christina; Pedersen Terje R;
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
The American journal of cardiology 2009;103(5):577-82.
2009: Koeijvoets Kristel C M C; Mooijaart Simon P; Dallinga-Thie Geesje M; Defesche Joep C; Steyerberg Ewout W; Westendorp Rudi G J; Kastelein John J P; van Hagen P Martin; Sijbrands Eric J G
Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia.
European heart journal 2009;30(5):618-23.
2009: van der Net Jeroen B; Janssens A Cecile J W; Defesche Joep C; Kastelein John J P; Sijbrands Eric J G; Steyerberg Ewout W
Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemia.
The American journal of cardiology 2009;103(3):375-80.
2009: Broekhuizen Lysette N; Mooij Hans L; Kastelein John J P; Stroes Erik S G; Vink Hans; Nieuwdorp Max
Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease.
Current opinion in lipidology 2009;20(1):57-62.
2009: van Leuven S I; Birjmohun R S; Franssen R; Bisoendial R J; de Kort H; Levels J H M; Basser R L; Meijers J C M; Kuivenhoven J A; Kastelein J J; Stroes E S
ApoAI-phosphatidylcholine infusion neutralizes the atherothrombotic effects of C-reactive protein in humans.
Journal of thrombosis and haemostasis : JTH 2009;7(2):347-54.
2009: Sankatsing Raaj R; Wit Ferdinand W; Vogel Martin; de Groot Eric; Brinkman Kees; Rockstroh Juergen K; Kastelein John J P; Stroes Erik S G; Reiss Peter
Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors.
Atherosclerosis 2009;202(2):589-95.
2009: El Harchaoui Karim; Arsenault Benoit J; Franssen Remco; Després Jean-Pierre; Hovingh G Kees; Stroes Erik S G; Otvos James D; Wareham Nicholas J; Kastelein John J P; Khaw Kay-Tee; Boekholdt S Matthijs
High-density lipoprotein particle size and concentration and coronary risk.
Annals of internal medicine 2009;150(2):84-93.
2009: van Wijk Diederik F; Stroes Erik S G; Kastelein John J P
Lipid measures and cardiovascular disease prediction.
Disease markers 2009;26(5-6):209-16.
2009: Birjmohun Rakesh S; Vergeer Menno; Stroes Erik S G; Sandhu Manjinder S; Ricketts Sally L; Tanck Michael W; Wareham Nicholas J; Jukema J Wouter; Kastelein John J P; Khaw Kay-Tee; Boekholdt S Matthijs
Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study.
PloS one 2009;4(8):e6809.
2008: Birjmohun Rakesh S; Kees Hovingh G; Stroes Erik S G; Hofstra Jorit J; Dallinga-Thie Geesje M; Meijers Joost C M; Kastelein John J P; Levi Marcel
Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema.
Clinical therapeutics 2008;30(12):2314-23.
2008: Vergeer Menno; Bots Michiel L; van Leuven Sander I; Basart Dick C; Sijbrands Eric J; Evans Gregory W; Grobbee Diederick E; Visseren Frank L; Stalenhoef Anton F; Stroes Erik S; Kastelein John J P
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Circulation 2008;118(24):2515-22.
2008: Sagoo Gurdeep S; Tatt Iain; Salanti Georgia; Butterworth Adam S; Sarwar Nadeem; van Maarle Merel; Jukema J Wouter; Wiman Björn; Kastelein John J P; Bennet Anna M; de Faire Ulf; Danesh John; Higgins Julian P T
Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: a HuGE association review and meta-analysis.
American journal of epidemiology 2008;168(11):1233-46.
2008: Koeijvoets Kristel C M C; van der Net Jeroen B; van Rossum Elisabeth F C; Steyerberg Ewout W; Defesche Joep C; Kastelein John J P; Lamberts Steven W J; Sijbrands Eric J G
Two common haplotypes of the glucocorticoid receptor gene are associated with increased susceptibility to cardiovascular disease in men with familial hypercholesterolemia.
The Journal of clinical endocrinology and metabolism 2008;93(12):4902-8.
2008: Ridker Paul M; Danielson Eleanor; Fonseca Francisco A H; Genest Jacques; Gotto Antonio M; Kastelein John J P; Koenig Wolfgang; Libby Peter; Lorenzatti Alberto J; MacFadyen Jean G; Nordestgaard Børge G; Shepherd James; Willerson James T; Glynn Robert J;
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
The New England journal of medicine 2008;359(21):2195-207.
2008: Brunham Liam R; Kastelein John J P; Hayden Michael R
ABCA1 gene mutations, HDL cholesterol levels, and risk of ischemic heart disease.
JAMA : the journal of the American Medical Association 2008;300(17):1997-8; author reply 1998.
2008: Regieli Jakub J; Jukema J Wouter; Grobbee Diederick E; Kastelein John J P; Kuivenhoven Jan Albert; Zwinderman Aeilko H; van der Graaf Yolanda; Bots Michiel L; Doevendans Pieter A
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
European heart journal 2008;29(22):2792-9.
2008: Visser Maartje E; Jakulj Lily; Kastelein John J P; Stroes Erik S G
LDL-C-lowering therapy: current and future therapeutic targets.
Current cardiology reports 2008;10(6):512-20.
2008: van der Graaf Anouk; Cuffie-Jackson Cynthia; Vissers Maud N; Trip Mieke D; Gagné Claude; Shi Genming; Veltri Enrico; Avis Hans J; Kastelein John J P
Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.
Journal of the American College of Cardiology 2008;52(17):1421-9.
2008: Boekholdt S Matthijs; de Winter Robbert J; Kastelein John J P
Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?
Circulation 2008;118(11):1120-2.
2008: Franssen Remco; Monajemi Houshang; Stroes Erik S G; Kastelein John J P
Obesity and dyslipidemia.
Endocrinology and metabolism clinics of North America 2008;37(3):623-33, viii.
2008: van der Net Jeroen B; Oosterveer Daniëlla M; Versmissen Jorie; Defesche Joep C; Yazdanpanah Mojgan; Aouizerat Bradley E; Steyerberg Ewout W; Malloy Mary J; Pullinger Clive R; Kastelein John J P; Kane John P; Sijbrands Eric J G
Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia.
European heart journal 2008;29(18):2195-201.
2008: van der Net Jeroen B; Janssens A Cecile J W; Eijkemans Marinus J C; Kastelein John J P; Sijbrands Eric J G; Steyerberg Ewout W
Cox proportional hazards models have more statistical power than logistic regression models in cross-sectional genetic association studies.
European journal of human genetics : EJHG 2008;16(9):1111-6.
2008: van Acker Bernadette A C; Botma Gert-Jan; Zwinderman Aeilko H; Kuivenhoven Jan Albert; Dallinga-Thie Geesje M; Sijbrands Eric J G; Boer Jolanda M A; Seidell Jacob C; Jukema J Wouter; Kastelein John J P; Jansen Hans; Verhoeven Adrie J M;
High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants.
Atherosclerosis 2008;200(1):161-7.
2008: Vissers Maud N; Trip Mieke D; Pritchard P Haydn; Tam Patrick; Lukic Tatjana; de Sain-van der Velden Monique G; de Barse Martina; Kastelein John J P
Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia.
European journal of clinical pharmacology 2008;64(7):651-61.
2008: Akdim Fatima; Kastelein John J P; Gaudet Daniel
The ENHANCE study and marketing ezetimibe.
JAMA : the journal of the American Medical Association 2008;299(23):2747; author reply 2747-8.
2008: Kastelein John J P; van der Steeg Wim A; Holme Ingar; Gaffney Michael; Cater Nilo B; Barter Philip; Deedwania Prakash; Olsson Anders G; Boekholdt S Matthijs; Demicco David A; Szarek Michael; LaRosa John C; Pedersen Terje R; Grundy Scott M;
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
Circulation 2008;117(23):3002-9.
2008: van der Graaf Anouk; Rodenburg Jessica; Vissers Maud N; Hutten Barbara A; Wiegman Albert; Trip Mieke D; Stroes Erik S G; Wijburg Frits A; Otvos James D; Kastelein John J P
Atherogenic lipoprotein particle size and concentrations and the effect of pravastatin in children with familial hypercholesterolemia.
The Journal of pediatrics 2008;152(6):873-8.
2008: Vergeer Menno; Kastelein John J P
Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia.
Nature clinical practice. Cardiovascular medicine 2008;5(6):302-3.
2008: van der Net Jeroen B; van Etten Jeroen; Yazdanpanah Mojgan; Dallinga-Thie Geesje M; Kastelein John J P; Defesche Joep C; Koopmans Richard P; Steyerberg Ewout W; Sijbrands Eric J G
Gene-load score of the renin-angiotensin-aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia.
European heart journal 2008;29(11):1370-6.
2008: Shah Sanjiv J; Waters David D; Barter Philip; Kastelein John J P; Shepherd James; Wenger Nanette K; DeMicco David A; Breazna Andrei; LaRosa John C
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
Journal of the American College of Cardiology 2008;51(20):1938-43.
2008: van der Graaf Anouk; Fouchier Sigrid W; Vissers Maud N; Defesche Joep C; Wiegman Albert; Sankatsing Raaj R; Hutten Barbara A; Trip Mieke D; Kastelein John J P
Familial defective apolipoprotein B and familial hypobetalipoproteinemia in one family: two neutralizing mutations.
Annals of internal medicine 2008;148(9):712-4.
2008: Shepherd James; Kastelein John J P; Bittner Vera; Deedwania Prakash; Breazna Andrei; Dobson Stephen; Wilson Daniel J; Zuckerman Andrea; Wenger Nanette K;
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Journal of the American College of Cardiology 2008;51(15):1448-54.
2008: Huijgen Roeland; Vissers Maud N; Defesche Joep C; Lansberg Peter J; Kastelein John J P; Hutten Barbara A
Familial hypercholesterolemia: current treatment and advances in management.
Expert review of cardiovascular therapy 2008;6(4):567-81.
2008: Nissen Steven E; Nicholls Stephen J; Wolski Kathy; Rodés-Cabau Josep; Cannon Christopher P; Deanfield John E; Després Jean-Pierre; Kastelein John J P; Steinhubl Steven R; Kapadia Samir; Yasin Muhammad; Ruzyllo Witold; Gaudin Christophe; Job Bernard; Hu Bo; Bhatt Deepak L; Lincoff A Michael; Tuzcu E Murat;
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
JAMA : the journal of the American Medical Association 2008;299(13):1547-60.
2008: Kastelein John J P; Akdim Fatima; Stroes Erik S G; Zwinderman Aeilko H; Bots Michiel L; Stalenhoef Anton F H; Visseren Frank L J; Sijbrands Eric J G; Trip Mieke D; Stein Evan A; Gaudet Daniel; Duivenvoorden Raphael; Veltri Enrico P; Marais A David; de Groot Eric;
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
The New England journal of medicine 2008;358(14):1431-43.
2008: Kastelein John J P; de Groot Eric
Ultrasound imaging techniques for the evaluation of cardiovascular therapies.
European heart journal 2008;29(7):849-58.
2008: Meuwese Marijn C; Trip Mieke D; van Wissen Sanne; van Miert Joram N I; Kastelein John J P; Stroes Erik S G
Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia.
Atherosclerosis 2008;197(2):916-21.
2008: Nieuwdorp Max; Meuwese Marijn C; Mooij Hans L; Ince Can; Broekhuizen Lysette N; Kastelein John J P; Stroes Erik S G; Vink Hans
Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability.
Journal of applied physiology (Bethesda, Md. : 1985) 2008;104(3):845-52.
2008: van der Steeg Wim A; Holme Ingar; Boekholdt S Matthijs; Larsen Mogens Lytken; Lindahl Christina; Stroes Erik S G; Tikkanen Matti J; Wareham Nicholas J; Faergeman Ole; Olsson Anders G; Pedersen Terje R; Khaw Kay-Tee; Kastelein John J P
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
Journal of the American College of Cardiology 2008;51(6):634-42.
2008: Homsma Sietske J M; Huijgen Roeland; Middeldorp Saskia; Sijbrands Eric J G; Kastelein John J P
Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance.
European journal of human genetics : EJHG 2008;16(1):14-7.
2008: van Leuven S I; Franssen R; Kastelein J J; Levi M; Stroes E S G; Tak P P
Systemic inflammation as a risk factor for atherothrombosis.
Rheumatology (Oxford, England) 2008;47(1):3-7.
2008: Bouhali Tarek; Brisson Diane; St-Pierre Julie; Tremblay Gerald; Perron Patrice; Laprise Catherine; Vohl Marie-Claude; Vissers Maud N; Hutten Barbara A; Després Jean-Pierre; Kastelein John J P; Gaudet Daniel
Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia.
Atherosclerosis 2008;196(1):262-9.
2008: Holme Ingar; Cater Nilo B; Faergeman Ole; Kastelein John J P; Olsson Anders G; Tikkanen Matti J; Larsen Mogens Lytken; Lindahl Christina; Pedersen Terje R;
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Annals of medicine 2008;40(6):456-64.
2008: Versmissen Jorie; Oosterveer Daniëlla M; Yazdanpanah Mojgan; Defesche Joep C; Basart Dick C G; Liem Anho H; Heeringa Jan; Witteman Jacqueline C; Lansberg Peter J; Kastelein John J P; Sijbrands Eric J G
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.
BMJ (Clinical research ed.) 2008;337():a2423.
2008: El Harchaoui Karim; Akdim Fatima; Stroes Erik S G; Trip Mieke D; Kastelein John J P
Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2008;8(4):233-42.
2008: van Leuven Sander I; Stroes Erik S; Kastelein John J P
High-density lipoprotein: a fall from grace?
Annals of medicine 2008;40(8):584-93.
2007: Kastelein John J P
Refocusing on use of cholesteryl ester transfer protein inhibitors.
The American journal of cardiology 2007;100(11 A):n47-52.
2007: Ridker Paul M; Fonseca Francisco A H; Genest Jacques; Gotto Antonio M; Kastelein John J P; Khurmi Nardev S; Koenig Wolfgang; Libby Peter; Lorenzatti Alberto J; Nordestgaard Borge G; Shepherd James; Willerson James T; Glynn Robert J;
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
The American journal of cardiology 2007;100(11):1659-64.
2007: Duivenvoorden Raphael; Nederveen Aart J; de Groot Eric; Kastelein John J P
Atherosclerosis imaging as a benchmark in the development of novel cardiovasular drugs.
Current opinion in lipidology 2007;18(6):613-21.
2007: van Leuven Sander I; Hezemans Rachel; Levels Johannes H; Snoek Susan; Stokkers Pieter C; Hovingh G Kees; Kastelein John J P; Stroes Erik S; de Groot Eric; Hommes Daan W
Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease.
Journal of lipid research 2007;48(12):2640-6.
2007: Bisoendial Radjesh J; Kastelein John J P; Stroes Erik S G
C-reactive protein and atherogenesis: from fatty streak to clinical event.
Atherosclerosis 2007;195(2):e10-8.
2007: Barter Philip J; Caulfield Mark; Eriksson Mats; Grundy Scott M; Kastelein John J P; Komajda Michel; Lopez-Sendon Jose; Mosca Lori; Tardif Jean-Claude; Waters David D; Shear Charles L; Revkin James H; Buhr Kevin A; Fisher Marian R; Tall Alan R; Brewer Bryan;
Effects of torcetrapib in patients at high risk for coronary events.
The New England journal of medicine 2007;357(21):2109-22.
2007: Birjmohun Rakesh S; Bisoendial Radjesh J; van Leuven Sander I; Ackermans Mariette; Zwinderman Aelko; Kastelein John J P; Stroes Erik S G; Sauerwein Hans P
A single bolus infusion of C-reactive protein increases gluconeogenesis and plasma glucose concentration in humans.
Metabolism: clinical and experimental 2007;56(11):1576-82.
2007: Arsenault Benoit J; Lemieux Isabelle; Després Jean-Pierre; Wareham Nicholas J; Luben Robert; Kastelein John J P; Khaw Kay-Tee; Boekholdt S Matthijs
Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study.
European heart journal 2007;28(22):2770-7.
2007: Shepherd James; Kastelein John J P; Bittner Vera; Deedwania Prakash; Breazna Andrei; Dobson Stephen; Wilson Daniel J; Zuckerman Andrea; Wenger Nanette K;
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Clinical journal of the American Society of Nephrology : CJASN 2007;2(6):1131-9.
2007: Birjmohun Rakesh S; Dallinga-Thie Geesje M; Kuivenhoven Jan Albert; Stroes Erik S G; Otvos James D; Wareham Nicholas J; Luben Robert; Kastelein John J P; Khaw Kay-Tee; Boekholdt S Matthijs
Apolipoprotein A-II is inversely associated with risk of future coronary artery disease.
Circulation 2007;116(18):2029-35.
2007: Nierman Melchior C; Rip Jaap; Kuivenhoven Jan Albert; Sakai Naohiko; Kastelein John J P; de Sain-van der Velden Monique G M; Stroes Erik S G; Prinsen Berthil H C M T
Enhanced apoB48 metabolism in lipoprotein lipase X447 homozygotes.
Atherosclerosis 2007;194(2):446-51.
2007: Barter Philip; Gotto Antonio M; LaRosa John C; Maroni Jaman; Szarek Michael; Grundy Scott M; Kastelein John J P; Bittner Vera; Fruchart Jean-Charles;
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
The New England journal of medicine 2007;357(13):1301-10.
2007: LaRosa John C; Grundy Scott M; Kastelein John J P; Kostis John B; Greten Heiner;
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
The American journal of cardiology 2007;100(5):747-52.
2007: Rip Jaap; Sierts Jeroen A; Vaessen Stefan F C; Kastelein John J P; Twisk Jaap; Kuivenhoven Jan Albert
Adeno-associated virus LPL(S447X) gene therapy in LDL receptor knockout mice.
Atherosclerosis 2007;194(1):55-61.
2007: El Harchaoui Karim; van der Steeg Wim A; Stroes Erik S G; Kastelein John J P
The role of CETP inhibition in dyslipidemia.
Current atherosclerosis reports 2007;9(2):125-33.
2007: Rodenburg Jessica; Vissers Maud N; Wiegman Albert; van Trotsenburg A S Paul; van der Graaf Anouk; de Groot Eric; Wijburg Frits A; Kastelein John J P; Hutten Barbara A
Statin treatment in children with familial hypercholesterolemia: the younger, the better.
Circulation 2007;116(6):664-8.
2007: Akdim Fatima; Stroes Erik S G; Kastelein John J P
Antisense apolipoprotein B therapy: where do we stand?
Current opinion in lipidology 2007;18(4):397-400.
2007: Schouten Olaf; Hoeks Sanne E; Welten Gijs M J M; Davignon Jean; Kastelein John J P; Vidakovic Radosav; Feringa Harm H H; Dunkelgrun Martin; van Domburg Ron T; Bax Jeroen J; Poldermans Don
Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
The American journal of cardiology 2007;100(2):316-20.
2007: Meuwese Marijn C; Stroes Erik S G; Hazen Stanley L; van Miert Joram N; Kuivenhoven Jan Albert; Schaub Robert G; Wareham Nicholas J; Luben Robert; Kastelein John J P; Khaw Kay-Tee; Boekholdt S Matthijs
Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.
Journal of the American College of Cardiology 2007;50(2):159-65.
2007: Ozsoy Riza C; van der Steeg Wim A; Kastelein John J P; Arisz Lambertus; Koopman Marion G
Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2007;22(6):1578-86.
2007: van der Steeg Wim A; Boekholdt S Matthijs; Stein Evan A; El-Harchaoui Karim; Stroes Erik S G; Sandhu Manjinder S; Wareham Nicholas J; Jukema J Wouter; Luben Robert; Zwinderman Aeilko H; Kastelein John J P; Khaw Kay-Tee
Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.
Annals of internal medicine 2007;146(9):640-8.
2007: Birjmohun Rakesh S; van Leuven Sander I; Levels Johannes H M; van 't Veer Cornelis; Kuivenhoven Jan Albert; Meijers Joost C M; Levi Marcel; Kastelein John J P; van der Poll Tom; Stroes Erik S G
High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(5):1153-8.
2007: Kastelein John J P; van Leuven Sander I; Evans Gregory W; Riley Ward A; Revkin James H; Shear Charles L; Bots Michiel L;
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
Current medical research and opinion 2007;23(4):885-94.
2007: Kastelein John J P; van Leuven Sander I; Burgess Leslie; Evans Greg W; Kuivenhoven Jan A; Barter Philip J; Revkin James H; Grobbee Diederick E; Riley Ward A; Shear Charles L; Duggan William T; Bots Michiel L;
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
The New England journal of medicine 2007;356(16):1620-30.
2007: Bisoendial Radjesh J; Kastelein John J P; Peters Stephan L M; Levels Johannes H M; Birjmohun Rakesh; Rotmans Joris I; Hartman Daniel; Meijers Joost C M; Levi Marcel; Stroes Erik S G
Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects.
Journal of lipid research 2007;48(4):952-60.
2007: van der Steeg Wim A; Hovingh G Kees; Klerkx Anke H E M; Hutten Barbara A; Nootenboom Inge C; Levels Johannes H M; van Tol Arie; Dallinga-Thie Gees M; Zwinderman Aeilko H; Kastelein John J P; Kuivenhoven Jan Albert
Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians.
Journal of lipid research 2007;48(3):674-82.
2007: Vaessen Stefan F C; Twisk Jaap; Kastelein John J P; Kuivenhoven Jan Albert
Gene therapy in disorders of lipoprotein metabolism.
Current gene therapy 2007;7(1):35-47.
2007: El Harchaoui Karim; van der Steeg Wim A; Stroes Erik S G; Kuivenhoven Jan Albert; Otvos James D; Wareham Nicholas J; Hutten Barbara A; Kastelein John J P; Khaw Kay-Tee; Boekholdt S Matthijs
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
Journal of the American College of Cardiology 2007;49(5):547-53.
2007: Khush Kiran K; Waters David D; Bittner Vera; Deedwania Prakash C; Kastelein John J P; Lewis Sandra J; Wenger Nanette K
Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study.
Circulation 2007;115(5):576-83.
2007: Souverein Olga W; Defesche Joep C; Zwinderman Aeilko H; Kastelein John J P; Tanck Michael W T
Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia.
European heart journal 2007;28(3):299-304.
2007: Penning-van Beest Fernie J A; Termorshuizen Fabian; Goettsch Wim G; Klungel Olaf H; Kastelein John J P; Herings Ron M C
Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study.
European heart journal 2007;28(2):154-9.
2007: Pinedo Sabine; Vissers Maud N; von Bergmann Klaus; Elharchaoui Karim; Lütjohann Dieter; Luben Robert; Wareham Nicholas J; Kastelein John J P; Khaw Kay-Tee; Boekholdt S Matthijs
Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study.
Journal of lipid research 2007;48(1):139-44.
2007: Akdim Fatima; van Leuven Sander I; Kastelein John J P; Stroes Erik S G
Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque?
Current pharmaceutical design 2007;13(10):1003-12.
2006: Ozsoy Riza C; van Leuven Sander I; Kastelein John J P; Arisz Lambertus; Koopman Marion G
The dyslipidemia of chronic renal disease: effects of statin therapy.
Current opinion in lipidology 2006;17(6):659-66.
2006: Waters David D; LaRosa John C; Barter Philip; Fruchart Jean-Charles; Gotto Antonio M; Carter Roddy; Breazna Andrei; Kastelein John J P; Grundy Scott M
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
Journal of the American College of Cardiology 2006;48(9):1793-9.
2006: Kastelein John J P; Wedel Mark K; Baker Brenda F; Su John; Bradley JoAnn D; Yu Rosie Z; Chuang Emil; Graham Mark J; Crooke Rosanne M
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.
Circulation 2006;114(16):1729-35.
2006: Rip Jaap; van Dijk Ko Willems; Sierts Jeroen A; Kastelein John J P; Twisk Jaap; Kuivenhoven Jan Albert
AAV1-LPL(S447X) gene therapy reduces hypertriglyceridemia in apoE2 knock in mice.
Biochimica et biophysica acta 2006;1761(10):1163-8.
2006: Koeijvoets Kristel C M C; van Rossum Elisabeth F C; Dallinga-Thie Geesje M; Steyerberg Ewout W; Defesche Joep C; Kastelein John J P; Lamberts Steven W J; Sijbrands Eric J G
A functional polymorphism in the glucocorticoid receptor gene and its relation to cardiovascular disease risk in familial hypercholesterolemia.
The Journal of clinical endocrinology and metabolism 2006;91(10):4131-6.
2006: Deedwania Prakash; Barter Philip; Carmena Rafael; Fruchart Jean-Charles; Grundy Scott M; Haffner Steven; Kastelein John J P; LaRosa John C; Schachner Holly; Shepherd James; Waters David D;
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Lancet 2006;368(9539):919-28.
2006: van Aalst-Cohen Emily S; Jansen Angelique C M; Tanck Michael W T; Defesche Joep C; Trip Mieke D; Lansberg Peter J; Stalenhoef Anton F H; Kastelein John J P
Diagnosing familial hypercholesterolaemia: the relevance of genetic testing.
European heart journal 2006;27(18):2240-6.
2006: Vaessen Stefan F C; Schaap Frank G; Kuivenhoven Jan-Albert; Groen Albert K; Hutten Barbara A; Boekholdt S Matthijs; Hattori Hiroaki; Sandhu Manjinder S; Bingham Sheila A; Luben Robert; Palmen Jutta A; Wareham Nicholas J; Humphries Steve E; Kastelein John J P; Talmud Philippa J; Khaw Kay-Tee
Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study.
Journal of lipid research 2006;47(9):2064-70.
2006: Meuwese Marijn C; Franssen Remco; Stroes Erik S G; Kastelein John J P
And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors.
Current opinion in lipidology 2006;17(4):426-30.
2006: Boekholdt S Matthijs; Hack C Erik; Sandhu Manjinder S; Luben Robert; Bingham Sheila A; Wareham Nicholas J; Peters Ron J G; Jukema J Wouter; Day Nicholas E; Kastelein John J P; Khaw Kay-Tee
C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003.
Atherosclerosis 2006;187(2):415-22.
2006: Roest Mark; Rodenburg Jessica; Wiegman Albert; Kastelein John J P; Voorbij Hieronymus A M
Paraoxonase genotype and carotid intima-media thickness in children with familial hypercholesterolemia.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2006;13(3):464-6.
2006: Maitland-van der Zee Anke-Hilse; Jukema J Wouter; Zwinderman Aeilko H; Hallman D Michael; De Boer Anthonius; Kastelein John J P; De Knijff Peter
Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS).
Acta cardiologica 2006;61(3):327-31.
2006: Rip Jaap; Nierman Melchior C; Ross Colin J; Jukema Jan Wouter; Hayden Michael R; Kastelein John J P; Stroes Erik S G; Kuivenhoven Jan Albert
Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(6):1236-45.
2006: Ross Colin J D; Twisk Jaap; Bakker Andrew C; Miao Fudan; Verbart Dennis; Rip Jaap; Godbey Tamara; Dijkhuizen Paul; Hermens Wim T J M C; Kastelein John J P; Kuivenhoven Jan Albert; Meulenberg Janneke M; Hayden Michael R
Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation.
Human gene therapy 2006;17(5):487-99.
2006: van der Graaf Anouk; Hutten Barbara A; Kastelein John J P; Vissers Maud N
Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
Expert review of cardiovascular therapy 2006;4(3):345-51.
2006: Rodenburg Jessica; Vissers Maud N; Wiegman Albert; Miller Elizabeth R; Ridker Paul M; Witztum Joseph L; Kastelein John J P; Tsimikas Sotirios
Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
Journal of the American College of Cardiology 2006;47(9):1803-10.
2006: Rana Jamal S; Jansen Angelique C; Zwinderman Aeilko H; Nieuwdorp Max; van Aalst-Cohen Emily S; Jukema J Wouter; Trip Mieke D; Kastelein John J P
Metabolic syndrome and risk of coronary, cerebral, and peripheral vascular disease in a large Dutch population with familial hypercholesterolemia.
Diabetes care 2006;29(5):1125-7.
2006: Jakulj Lily; Vissers Maud N; Rodenburg Jessica; Wiegman Albert; Trip Mieke D; Kastelein John J P
Plant stanols do not restore endothelial function in pre-pubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels.
The Journal of pediatrics 2006;148(4):495-500.
2006: Nieuwdorp Max; Mooij Hans L; Kroon Jojanneke; Atasever Bektas; Spaan Jos A E; Ince Can; Holleman Frits; Diamant Michaela; Heine Robert J; Hoekstra Joost B L; Kastelein John J P; Stroes Erik S G; Vink Hans
Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes.
Diabetes 2006;55(4):1127-32.
2006: Klerkx Anke H E M; El Harchaoui Karim; van der Steeg Wim A; Boekholdt S Matthijs; Stroes Erik S G; Kastelein John J P; Kuivenhoven Jan Albert
Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(4):706-15.
2006: Rip Jaap; Nierman Melchior C; Wareham Nicholas J; Luben Robert; Bingham Sheila A; Day Nicholas E; van Miert Joram N I; Hutten Barbara A; Kastelein John J P; Kuivenhoven Jan Albert; Khaw Kay-Tee; Boekholdt S Matthijs
Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(3):637-42.
2006: Barter Philip J; Kastelein John J P
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
Journal of the American College of Cardiology 2006;47(3):492-9.
2006: Nieuwdorp Max; van Haeften Timon W; Gouverneur Mirella C L G; Mooij Hans L; van Lieshout Miriam H P; Levi Marcel; Meijers Joost C M; Holleman Frits; Hoekstra Joost B L; Vink Hans; Kastelein John J P; Stroes Erik S G
Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo.
Diabetes 2006;55(2):480-6.
2006: van Leuven Sander I; Kastelein John J P; Allison Anthony C; Hayden Michael R; Stroes Erik S G
Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles?
Cardiovascular research 2006;69(2):341-7.
2006: Vriend Joris W J; de Groot Eric; de Waal Tim T; Zijta Frank M; Kastelein John J P; Mulder Barbara J M
Increased carotid and femoral intima-media thickness in patients after repair of aortic coarctation: influence of early repair.
American heart journal 2006;151(1):242-7.
2006: Kramer Anneke; Jansen Angelique C M; van Aalst-Cohen Emily S; Tanck Michael W T; Kastelein John J P; Zwinderman Aeilko H
Relative risk for cardiovascular atherosclerotic events after smoking cessation: 6-9 years excess risk in individuals with familial hypercholesterolemia.
BMC public health 2006;6():262.
2005: Fouchier Sigrid W; Kastelein John J P; Defesche Joep C
Update of the molecular basis of familial hypercholesterolemia in The Netherlands.
Human mutation 2005;26(6):550-6.
2005: Fouchier Sigrid W; Rodenburg Jessica; Defesche Joep C; Kastelein John J P
Management of hereditary dyslipidaemia; the paradigm of autosomal dominant hypercholesterolaemia.
European journal of human genetics : EJHG 2005;13(12):1247-53.
2005: Jakulj Lily; Trip Mieke D; Sudhop Thomas; von Bergmann Klaus; Kastelein John J P; Vissers Maud N
Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels.
Journal of lipid research 2005;46(12):2692-8.
2005: Kastelein John J P
Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
The American journal of cardiology 2005;96(9A):20K-27K; discussion 34K-35K.
2005: Pedersen Terje R; Faergeman Ole; Kastelein John J P; Olsson Anders G; Tikkanen Matti J; Holme Ingar; Larsen Mogens Lytken; Bendiksen Fredrik S; Lindahl Christina; Szarek Michael; Tsai John;
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2005;294(19):2437-45.
2005: Koeijvoets Kristel C M C; Rodenburg Jessica; Hutten Barbara A; Wiegman Albert; Kastelein John J P; Sijbrands Eric J G
Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial.
Circulation 2005;112(20):3168-73.
2005: Rip Jaap; Nierman Melchior C; Sierts Jeroen A; Petersen Wilma; Van den Oever Karin; Van Raalte Daniel; Ross Colin J D; Hayden Michael R; Bakker Andrew C; Dijkhuizen Paul; Hermens Wim T; Twisk Jaap; Stroes Erik; Kastelein John J P; Kuivenhoven Jan Albert; Meulenberg Janneke M
Gene therapy for lipoprotein lipase deficiency: working toward clinical application.
Human gene therapy 2005;16(11):1276-86.
2005: Nierman Melchior C; Rip Jaap; Kuivenhoven Jan-Albert; van Raalte Daniel H; Hutten Barbara A; Sakai Naohiko; Kastelein John J P; Stroes Erik S G
Carriers of the frequent lipoprotein lipase S447X variant exhibit enhanced postprandial apoprotein B-48 clearance.
Metabolism: clinical and experimental 2005;54(11):1499-503.
2005: Nierman Melchior C; Prinsen Berthil H C M T; Rip Jaap; Veldman Robert Jan; Kuivenhoven Jan Albert; Kastelein John J P; de Sain-van der Velden Monique G M; Stroes Erik S G
Enhanced conversion of triglyceride-rich lipoproteins and increased low-density lipoprotein removal in LPLS447X carriers.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(11):2410-5.
2005: Rana Jamal S; Monraats Pascalle S; Zwinderman Aeilko H; de Maat Moniek P M; Kastelein John J P; Agema Willem R P; Doevendans Pieter A F; de Winter Robbert J; Tio René A; Waltenberger Johannes; Frants Rune R; van der Laarse Arnoud; van der Wall Ernst E; Jukema J Wouter
Pre-procedural levels of erythrocyte sedimentation rate (ESR) and risk of clinical restenosis in patients with percutaneous coronary intervention and coronary stent placement.
Thrombosis and haemostasis 2005;94(4):892-4.
2005: Nieuwdorp Max; Meuwese Marijn C; Vink Hans; Hoekstra Joost B L; Kastelein John J P; Stroes Erik S G
The endothelial glycocalyx: a potential barrier between health and vascular disease.
Current opinion in lipidology 2005;16(5):507-11.
2005: van Leuven Sander I; Kastelein John J P; Hayden Michael R; d'Cruz David; Hughes Graham R; Stroes Erik S
Cardiovascular disease in systemic lupus erythematosus: has the time for action come?
Current opinion in lipidology 2005;16(5):501-6.
2005: van Aalst-Cohen Emily S; Jansen Angelique C M; Boekholdt S Matthijs; Tanck Michael W T; Fontecha Marcel R; Cheng Suzanne; Li Jia; Defesche Joep C; Kuivenhoven Jan Albert; Kastelein John J P
Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia.
European journal of human genetics : EJHG 2005;13(10):1137-42.
2005: Monraats Pascalle S; Rana Jamal S; Nierman Melchior C; Pires Nuno M M; Zwinderman Aeilko H; Kastelein John J P; Kuivenhoven Jan Albert; de Maat Moniek P M; Rittersma Saskia Z H; Schepers Abbey; Doevendans Pieter A F; de Winter Robbert J; Tio René A; Frants Rune R; Quax Paul H A; van der Laarse Arnoud; van der Wall Ernst E; Jukema J Wouter
Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention.
Journal of the American College of Cardiology 2005;46(6):1093-100.
2005: Vriend Joris W J; Engelfriet Peter M; de Groot Eric; Elsen Bart M; Kastelein John J P; Mulder Barbara J M
Age at repair and left ventricular mass in patients after repair of aortic coarctation.
The Journal of thoracic and cardiovascular surgery 2005;130(3):896-7.
2005: Bisoendial Radjesh J; Hovingh G Kees; El Harchaoui Karim; Levels Johannes H M; Tsimikas Sotirios; Pu Kewei; Zwinderman Aeilko E; Kuivenhoven Jan Albert; Kastelein John J P; Stroes Erik S G
Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(9):e133-4.
2005: Frisdal Eric; Klerkx Anke H E M; Le Goff Wilfried; Tanck Michael W T; Lagarde Jean-Pierre; Jukema J Wouter; Kastelein John J P; Chapman M John; Guerin Maryse
Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study.
Human molecular genetics 2005;14(18):2607-18.
2005: Sankatsing Raaj R; Fouchier Sigrid W; de Haan Stefan; Hutten Barbara A; de Groot Eric; Kastelein John J P; Stroes Erik S G
Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(9):1979-84.
2005: Hovingh G Kees; Hutten Barbara A; Holleboom Adriaan G; Petersen Wilma; Rol Patrick; Stalenhoef Anton; Zwinderman Aeilko H; de Groot Eric; Kastelein John J P; Kuivenhoven Jan Albert
Compromised LCAT function is associated with increased atherosclerosis.
Circulation 2005;112(6):879-84.
2005: Sankatsing Raaj R; de Groot Eric; Jukema J Wouter; de Feyter Pim J; Pennell Dudley J; Schoenhagen Paul; Nissen Steven E; Stroes Erik S G; Kastelein John J P
Surrogate markers for atherosclerotic disease.
Current opinion in lipidology 2005;16(4):434-41.
2005: Jansen Angelique C M; van Aalst-Cohen Emily S; Tanck Michael W T; Cheng Suzanne; Fontecha Marcel R; Li Jia; Defesche Joep C; Kastelein John J P
Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(7):1475-81.
2005: van Leuven Sander I; Kastelein John J P
Atorvastatin.
Expert opinion on pharmacotherapy 2005;6(7):1191-203.
2005: Kastelein John J P; Fouchier Sigrid W; Defesche Joep C
What promise does PCSK9 hold?
Journal of the American College of Cardiology 2005;45(10):1620-1.
2005: Kuivenhoven Jan Albert; de Grooth Greetje J; Kawamura Hitoshi; Klerkx Anke H; Wilhelm Francois; Trip Mieke D; Kastelein John J P
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
The American journal of cardiology 2005;95(9):1085-8.
2005: Koeijvoets Kristel C M C; Wiegman Albert; Rodenburg Jessica; Defesche Joep C; Kastelein John J P; Sijbrands Eric J G
Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study.
Atherosclerosis 2005;180(1):93-9.
2005: Wegman Jurgen J; Hu Xiaofeng; Tan Hendra; Bergen Arthur A B; Trip Mieke D; Kastelein John J P; Smulders Yvo M
Patients with premature coronary artery disease who carry the ABCC6 R1141X mutation have no Pseudoxanthoma Elasticum phenotype.
International journal of cardiology 2005;100(3):389-93.
2005: Rana Jamal S; Monraats Pascalle S; Zwinderman Aeilko H; de Maat Moniek P M; Kastelein John J P; Doevendans Pieter A F; de Winter Robbert J; Tio René A; Frants Rune R; van der Laarse Arnoud; van der Wall Ernst E; Jukema J Wouter;
Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention.
Diabetes care 2005;28(4):873-7.
2005: Bisoendial Radjesh J; Kastelein John J P; Levels Johannes H M; Zwaginga Jaap J; van den Bogaard Bas; Reitsma Pieter H; Meijers Joost C M; Hartman Daniel; Levi Marcel; Stroes Erik S G
Activation of inflammation and coagulation after infusion of C-reactive protein in humans.
Circulation research 2005;96(7):714-6.
2005: Hovingh G Kees; de Groot Eric; van der Steeg Wim; Boekholdt S Matthijs; Hutten Barbara A; Kuivenhoven Jan Albert; Kastelein John J P
Inherited disorders of HDL metabolism and atherosclerosis.
Current opinion in lipidology 2005;16(2):139-45.
2005: LaRosa John C; Grundy Scott M; Waters David D; Shear Charles; Barter Philip; Fruchart Jean-Charles; Gotto Antonio M; Greten Heiner; Kastelein John J P; Shepherd James; Wenger Nanette K;
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
The New England journal of medicine 2005;352(14):1425-35.
2005: Boekholdt S Matthijs; Keller Tymen T; Wareham Nicholas J; Luben Robert; Bingham Sheila A; Day Nicholas E; Sandhu Manjinder S; Jukema J Wouter; Kastelein John J P; Hack C Erik; Khaw Kay-Tee
Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(4):839-46.
2005: Jansen Angelique C M; van Aalst-Cohen Emily S; Hutten Barbara A; Büller Harry R; Kastelein John J P; Prins Martin H
Guidelines were developed for data collection from medical records for use in retrospective analyses.
Journal of clinical epidemiology 2005;58(3):269-74.
2005: van Himbergen Thomas M; Roest Mark; de Graaf Jacqueline; Jansen Eugène H J M; Hattori Hiroaki; Kastelein John J P; Voorbij Hieronymus A M; Stalenhoef Anton F H; van Tits Lambertus J H
Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia.
Journal of lipid research 2005;46(3):445-51.
2005: Kastelein John J P; Sager Philip T; de Groot Eric; Veltri Enrico
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial.
American heart journal 2005;149(2):234-9.
2005: Roest Mark; Jansen Angelique C M; Barendrecht Arjan; Leus Frank R; Kastelein John J P; Voorbij Hieronymus A M
Variation at the paraoxonase gene locus contributes to carotid arterial wall thickness in subjects with familial hypercholesterolemia.
Clinical biochemistry 2005;38(2):123-7.
2005: Birjmohun Rakesh S; Hutten Barbara A; Kastelein John J P; Stroes Erik S G
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Journal of the American College of Cardiology 2005;45(2):185-97.
2005: van Wissen Sanne; Smilde Tineke J; Trip Mieke D; Stalenhoef Anton F H; Kastelein John J P
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia.
The American journal of cardiology 2005;95(2):264-6.
2005: Vriend Joris W J; Zwinderman Aeiko H; de Groot Eric; Kastelein John J P; Bouma Berto J; Mulder Barbara J M
Predictive value of mild, residual descending aortic narrowing for blood pressure and vascular damage in patients after repair of aortic coarctation.
European heart journal 2005;26(1):84-90.
2004: Foucher Christelle; Rattier Stephanie; Flavell David M; Talmud Philippa J; Humphries Steve E; Kastelein John J P; Ayyobi Amir; Pimstone Simon; Frohlich Jiri; Ansquer Jean-Claude; Steiner George;
Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.
Pharmacogenetics 2004;14(12):823-9.
2004: Rodenburg Jessica; Vissers Maud N; Daniels Stephen R; Wiegman Albert; Kastelein John J P
Lipid-lowering medications.
Pediatric endocrinology reviews : PER 2004;2 Suppl 1():171-80.
2004: de Grooth Greetje J; Klerkx Anke H E M; Stroes Erik S G; Stalenhoef Anton F H; Kastelein John J P; Kuivenhoven Jan Albert
A review of CETP and its relation to atherosclerosis.
Journal of lipid research 2004;45(11):1967-74.
2004: van Leth Frank; Phanuphak Prahpan; Stroes Erik; Gazzard Brian; Cahn Pedro; Raffi François; Wood Robin; Bloch Mark; Katlama Christine; Kastelein John J P; Schechter Mauro; Murphy Robert L; Horban Andrzej; Hall David B; Lange Joep M A; Reiss Peter
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
PLoS medicine 2004;1(1):e19.
2004: Kastelein John J P
Should rosuvastatin be withdrawn from the market?
Lancet 2004;364(9445):1577-8; author reply 1578-9.
2004: Shepherd James; Hunninghake Donald B; Stein Evan A; Kastelein John J P; Harris Susan; Pears John; Hutchinson Howard G
Safety of rosuvastatin.
The American journal of cardiology 2004;94(7):882-8.
2004: Hovingh G Kees; Brownlie Alison; Bisoendial Radjesh J; Dube Marie Pierre; Levels Johannes H M; Petersen Wilma; Dullaart Robin P F; Stroes Erik S G; Zwinderman Aeilko H; de Groot Eric; Hayden Michael R; Kuivenhoven Jan Albert; Kastelein John J P
A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease.
Journal of the American College of Cardiology 2004;44(7):1429-35.
2004: Pedersen Terje R; Faergeman Ole; Kastelein John J P; Olsson Anders G; Tikkanen Matti J; Holme Ingar; Larsen Mogens Lytken; Bendiksen Fredrik S; Lindahl Christina; Palmer Gary;
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
The American journal of cardiology 2004;94(6):720-4.
2004: Ross Colin J D; Twisk Jaap; Meulenberg Janneke M; Liu Guoqing; van den Oever Karin; Moraal Ewoud; Hermens Wim T; Rip Jaap; Kastelein John J P; Kuivenhoven Jan Albert; Hayden Michael R
Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation.
Human gene therapy 2004;15(9):906-19.
2004: Boekholdt S Matthijs; Kuivenhoven Jan-Albert; Wareham Nicholas J; Peters Ron J G; Jukema J Wouter; Luben Robert; Bingham Sheila A; Day Nicholas E; Kastelein John J P; Khaw Kay-Tee
Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.
Circulation 2004;110(11):1418-23.
2004: Agema Willem R P; de Maat Moniek P M; Zwinderman Aeilko H; Kastelein John J P; Rabelink Ton J; van Boven Ad J; Feskens Edith J M; Boer Jolanda M A; van der Wall Ernst E; Jukema J Wouter
An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men.
Clinical science (London, England : 1979) 2004;107(3):255-61.
2004: Fouchier Sigrid W; Defesche Joep C; Kastelein John J P; Sijbrands Eric J G
Familial defective apolipoprotein B versus familial hypercholesterolemia: an assessment of risk.
Seminars in vascular medicine 2004;4(3):259-64.
2004: Maitland-van der Zee Anke-Hilse; Stricker Bruno H Ch; Klungel Olaf H; Kastelein John J P; Hofman Albert; Witteman Jacqueline C M; Leufkens Hubertus G M; Duijn Cornelia M van; Boer Ad Anthonius de
Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism.
Atherosclerosis 2004;175(2):377-9.
2004: Rodenburg J; Vissers M N; Wiegman A; Trip M D; Bakker H D; Kastelein John J P
Familial hypercholesterolemia in children.
Current opinion in lipidology 2004;15(4):405-11.
2004: Boekholdt S Matthijs; Kuivenhoven Jan-Albert; Hovingh G Kees; Jukema J Wouter; Kastelein John J P; van Tol Arie
CETP gene variation: relation to lipid parameters and cardiovascular risk.
Current opinion in lipidology 2004;15(4):393-8.
2004: Wiegman Albert; Hutten Barbara A; de Groot Eric; Rodenburg Jessica; Bakker Henk D; Büller Harry R; Sijbrands Eric J G; Kastelein John J P
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2004;292(3):331-7.
2004: de Groot Eric; Hovingh G Kees; Wiegman Albert; Duriez Patrick; Smit Andries J; Fruchart Jean-Charles; Kastelein John J P
Measurement of arterial wall thickness as a surrogate marker for atherosclerosis.
Circulation 2004;109(23 Suppl 1):III33-8.
2004: Fruchart Jean-Charles; Nierman Melchior C; Stroes Erik S G; Kastelein John J P; Duriez Patrick
New risk factors for atherosclerosis and patient risk assessment.
Circulation 2004;109(23 Suppl 1):III15-9.
2004: Agema Willem R P; Wouter Jukema J; de Maat Moniek P M; Zwinderman Aeilko H; Kastelein John J P; Rabelink Ton J; van der Wall Ernst E
Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis.
Thrombosis and haemostasis 2004;91(5):986-90.
2004: Rotmans Joris I; Verhagen Hence J M; Velema Evelyn; de Kleijn Dominique P V; van den Heuvel Mieke; Kastelein John J P; Pasterkamp Gerard; Stroes Erik S G
Local overexpression of C-type natriuretic peptide ameliorates vascular adaptation of porcine hemodialysis grafts.
Kidney international 2004;65(5):1897-905.
2004: van Tits Lambertus J H; Smilde Tineke J; van Wissen Sanne; de Graaf Jacqueline; Kastelein John J P; Stalenhoef Anton F H
Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2004;52(3):177-84.
2004: de Grooth Greetje J; Smilde Tineke J; Van Wissen Sanne; Klerkx Anke H E M; Zwinderman Aeilko H; Fruchart Jean-Charles; Kastelein John J P; Stalenhoef Anton F H; Kuivenhoven Jan Albert
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.
Atherosclerosis 2004;173(2):261-7.
2004: Kastelein John J P; de Groot Eric; Sankatsing Raaj
Atherosclerosis measured by B-mode ultrasonography: effect of statin therapy on disease progression.
The American journal of medicine 2004;116 Suppl 6A():31S-36S.
2004: Kastelein John J P; Stroes Erik S G; de Groot Eric
Subclinical atherosclerosis as a target of therapy: potential role of statins.
The American journal of cardiology 2004;93(6):737-40.
2004: de Grooth Greetje J; Zerba Kim E; Huang Shu-Pang; Tsuchihashi Zenta; Kirchgessner Todd; Belder René; Vishnupad Priya; Hu Beihong; Klerkx Anke H E M; Zwinderman Aeilko H; Jukema J Wouter; Sacks Frank M; Kastelein John J P; Kuivenhoven Jan Albert
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
Journal of the American College of Cardiology 2004;43(5):854-7.
2004: Wonderling David; Umans-Eckenhausen Marina A W; Marks Dalya; Defesche Joep C; Kastelein John J P; Thorogood Margaret
Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
Seminars in vascular medicine 2004;4(1):97-104.
2004: Defesche Joep C; Lansberg Peter J; Umans-Eckenhausen Marina A W; Kastelein John J P
Advanced method for the identification of patients with inherited hypercholesterolemia.
Seminars in vascular medicine 2004;4(1):59-65.
2004: van Aalst-Cohen Emily S; Jansen Angelique C M; de Jongh Saskia; de Sauvage Nolting Pernette R W; Kastelein John J P
Clinical, diagnostic, and therapeutic aspects of familial hypercholesterolemia.
Seminars in vascular medicine 2004;4(1):31-41.
2004: Maitland-van der Zee Anke Hilse; Klungel Olaf H; Stricker Bruno H Ch; Veenstra David L; Kastelein John J P; Hofman Albert; Witteman Jacqueline C M; Leufkens Hubertus G M; van Duijn Cornelia M; de Boer Anthonius
Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men.
Pharmacogenetics 2004;14(1):53-60.
2004: Wiegman Albert; de Groot Eric; Hutten Barbara A; Rodenburg Jessica; Gort Johan; Bakker Henk D; Sijbrands Eric J G; Kastelein John J P
Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia.
Lancet 2004;363(9406):369-70.
2004: Boekholdt S Matthijs; Peters Ron J G; de Maat Moniek P M; Zwinderman Aeilko H; van Der Wall Ernst E; Reitsma Pieter H; Jukema J Wouter; Kastelein John J P
Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events.
American heart journal 2004;147(1):181-6.
2004: Wiersma Heleen E; Wiegman Albert; Koopmans Richard P; Bakker Henk D; Kastelein John J P; van Boxtel Chris J
Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia.
Clinical drug investigation 2004;24(2):113-20.
2003: van Wissen Sanne; Smilde Tineke J; de Groot Eric; Hutten Barbara A; Kastelein John J P; Stalenhoef Anton F H
The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2003;10(6):451-5.
2003: Boekholdt S Matthijs; Peters Ron J G; Fountoulaki Katerina; Kastelein John J P; Sijbrands Eric J G
Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis.
Human genetics 2003;113(5):417-25.
2003: Nolting Pernette R W de Sauvage; de Groot Eric; Zwinderman Aeilko H; Buirma Rudolf J A; Trip Mieke D; Kastelein John J P
Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin.
Archives of internal medicine 2003;163(15):1837-41.
2003: Singaraja Roshni R; Brunham Liam R; Visscher Henk; Kastelein John J P; Hayden Michael R
Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(8):1322-32.
2003: Bisoendial Radjesh J; Hovingh G Kees; Levels Johannes H M; Lerch Peter G; Andresen Irmgard; Hayden Michael R; Kastelein John J P; Stroes Erik S G
Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein.
Circulation 2003;107(23):2944-8.
2003: Hovingh G Kees; Van Wijland Michel J A; Brownlie Alison; Bisoendial Radjesh J; Hayden Michael R; Kastelein John J P; Groen Albert K
The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia.
Journal of lipid research 2003;44(6):1251-5.
2003: Wiegman Albert; Sijbrands Eric J G; Rodenburg Jessica; Defesche Joep C; de Jongh Saskia; Bakker Henk D; Kastelein John J P
The apolipoprotein epsilon4 allele confers additional risk in children with familial hypercholesterolemia.
Pediatric research 2003;53(6):1008-12.
2003: Boekholdt S Matthijs; Agema Willem R P; Peters Ron J G; Zwinderman Aeilko H; van der Wall Ernst E; Reitsma Pieter H; Kastelein John J P; Jukema J Wouter;
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
Circulation 2003;107(19):2416-21.
2003: Elrayess Mohamed A; Webb Karen E; Flavell David M; Syvänne Mikko; Taskinen Marja-Riitta; Frick M Heikki; Nieminen Markku S; Kesäniemi Y Antero; Pasternack Amos; Jukema J Wouter; Kastelein John J P; Zwinderman Aeilko H; Humphries Steve E
A novel functional polymorphism in the PECAM-1 gene (53G>A) is associated with progression of atherosclerosis in the LOCAT and REGRESS studies.
Atherosclerosis 2003;168(1):131-8.
2003: Maitland-van der Zee Anke-Hilse; Stricker Bruno H Ch; Klungel Olaf H; Mantel-Teeuwisse Aukje K; Kastelein John J P; Hofman Albert; Leufkens Hubertus G M; van Duijn Cornelia M; de Boer Anthonius
Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes.
Pharmacogenetics 2003;13(4):219-23.
2003: Kastelein John J P; Wiegman Albert; de Groot Eric
Surrogate markers of atherosclerosis: impact of statins.
Atherosclerosis. Supplements 2003;4(1):31-6.
2003: Wiegman Albert; Rodenburg Jessica; de Jongh Saskia; Defesche Joep C; Bakker Henk D; Kastelein John J P; Sijbrands Eric J G
Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children.
Circulation 2003;107(11):1473-8.
2003: Trip Mieke D; van Wissen Sanne; Smilde Tineke J; Hutten Barbara A; Stalenhoef Anton F H; Kastelein John J P
Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia.
The American journal of cardiology 2003;91(5):604-6.
2003: Semb Anne G; van Wissen Sanne; Ueland Thor; Smilde Tineke; Waehre Torgun; Tripp Mieke D; Frøland Stig S; Kastelein John J P; Gullestad Lars; Pedersen Terje R; Aukrust Pål; Stalenhoef Anton F H
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
Journal of the American College of Cardiology 2003;41(2):275-9.
2003: Umans-Eckenhausen Marina A W; Defesche Joep C; van Dam Marjel J; Kastelein John J P
Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia.
Archives of internal medicine 2003;163(1):65-8.
2003: Klerkx Anke H E M; Tanck Michael W T; Kastelein John J P; Molhuizen Henri O F; Jukema J Wouter; Zwinderman Aeilko H; Kuivenhoven Jan Albert
Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-->A polymorphism and a novel promoter variant are independently associated with CETP concentration.
Human molecular genetics 2003;12(2):111-23.
2002: de Jongh Saskia; Lilien Marc R; op't Roodt Jos; Stroes Erik S G; Bakker Henk D; Kastelein John J P
Early statin therapy restores endothelial function in children with familial hypercholesterolemia.
Journal of the American College of Cardiology 2002;40(12):2117-21.
2002: Boekholdt S Matthijs; Trip Mieke D; Peters Ron J G; Engelen Marc; Boer Jolanda M A; Feskens Edith J M; Zwinderman Aeilko H; Kastelein John J P; Reitsma Pieter H
Thrombospondin-2 polymorphism is associated with a reduced risk of premature myocardial infarction.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(12):e24-7.
2002: Umans-Eckenhausen Marina A W; Sijbrands Eric J G; Kastelein John J P; Defesche Joep C
Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population.
Circulation 2002;106(24):3031-6.
2002: Bisoendial Radjesh J; Hovingh G Kees; de Groot Eric; Kastelein John J P; Lansberg Peter J; Stroes Erik S G
Measurement of subclinical atherosclerosis: beyond risk factor assessment.
Current opinion in lipidology 2002;13(6):595-603.
2002: van Wissen Sanne; Trip Mieke D; Smilde Tineke J; de Graaf Jacqueline; Stalenhoef Anton F H; Kastelein John J P
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy.
Atherosclerosis 2002;165(2):361-6.
2002: De Graaf Jacqueline; De Sauvage Nolting Pernette R W; Van Dam Marjel; Belsey Elizabeth M; Kastelein John J P; Haydn Pritchard P; Stalenhoef Anton F H
Consumption of tall oil-derived phytosterols in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-cholesterol levels.
The British journal of nutrition 2002;88(5):479-88.
2002: Wellington Cheryl L; Yang Yu-Zhou; Zhou Stephen; Clee Susanne M; Tan Bing; Hirano Kenichi; Zwarts Karin; Kwok Anita; Gelfer Allison; Marcil Michel; Newman Scott; Roomp Kirsten; Singaraja Roshni; Collins Jennifer; Zhang Lin-Hua; Groen Albert K; Hovingh Kees; Brownlie Alison; Tafuri Sherrie; Genest Jacques; Kastelein John J P; Hayden Michael R
Truncation mutations in ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol.
Journal of lipid research 2002;43(11):1939-49.
2002: de Jongh Saskia; Ose Leiv; Szamosi Tamás; Gagné Claude; Lambert M; Scott Russell; Perron P; Dobbelaere Dries; Saborio M; Tuohy Mary B; Stepanavage Michael; Sapre Aditi; Gumbiner Barry; Mercuri Michele; van Trotsenburg A S Paul; Bakker Henk D; Kastelein John J P;
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin.
Circulation 2002;106(17):2231-7.
2002: Attie Alan D; Hamon Yannick; Brooks-Wilson Angela R; Gray-Keller Mark P; MacDonald Marcia L E; Rigot Veronique; Tebon Angie; Zhang Lin-Hua; Mulligan Jacob D; Singaraja Roshni R; Bitgood J James; Cook Mark E; Kastelein John J P; Chimini Giovanna; Hayden Michael R
Identification and functional analysis of a naturally occurring E89K mutation in the ABCA1 gene of the WHAM chicken.
Journal of lipid research 2002;43(10):1610-7.
2002: de Sauvage Nolting Pernette R W; Buirma Rudolf J A; Hutten Barbara A; Kastelein John J P;
Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in Statin studies with familial hypercholesterolemia (ExPRESS FH).
Atherosclerosis 2002;164(2):347-54.
2002: de Sauvage Nolting Pernette R W; Twickler Marcel B; Dallinga-Thie Geesje M; Buirma Rudolf J A; Hutten Barbara A; Kastelein John J P;
Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy.
Circulation 2002;106(7):788-92.
2002: Trip Mieke D; Smulders Yvo M; Wegman Jurgen J; Hu Xiaofeng; Boer Jolanda M A; ten Brink Jacoline B; Zwinderman Aeilko H; Kastelein John J P; Feskens Edith J M; Bergen Arthur A B
Frequent mutation in the ABCC6 gene (R1141X) is associated with a strong increase in the prevalence of coronary artery disease.
Circulation 2002;106(7):773-5.
2002: Maitland-van der Zee Anke Hilse; Klungel Olaf H; Stricker Bruno H Ch; Monique Verschuren W M; Kastelein John J P; Leufkens Hubertus G M; de Boer Anthonius
Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.
Atherosclerosis 2002;163(2):213-22.
2002: Evans Valerie; Kastelein John J P
Lipoprotein lipase deficiency--rare or common?
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2002;16(4):283-7.
2002: de Sauvage Nolting Pernette R W; Buirma Rudolf J A; Hutten Barbara A; Kastelein John J P;
Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]).
The American journal of cardiology 2002;90(2):181-4.
2002: de Jongh Saskia; Lilien Marc R; Bakker Henk D; Hutten Barbara A; Kastelein John J P; Stroes Erik S G
Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia.
Atherosclerosis 2002;163(1):193-7.
2002: de Grooth Greetje J; Kuivenhoven Jan Albert; Stalenhoef Anton F H; de Graaf Jacqueline; Zwinderman Aeilko H; Posma Jan L; van Tol Arie; Kastelein John J P
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.
Circulation 2002;105(18):2159-65.
2002: van Dam Marjel; van Wissen Sanne; Kastelein John J P
Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol.
Journal of cardiovascular risk 2002;9(2):89-95.
2002: Jansen Angelique C M; van Wissen Sanne; Defesche Joep C; Kastelein John J P
Phenotypic variability in familial hypercholesterolaemia: an update.
Current opinion in lipidology 2002;13(2):165-71.
2002: de Beer Femke; Stalenhoef Anton F H; Hoogerbrugge Nicoline; Kastelein John J P; Gevers Leuven Jan A; van Duijn Cornelia M; Havekes Louis M; Smelt Augustinus H M
Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(2):294-9.
2002: van Dam Marjel J; de Groot Eric; Clee Susanne M; Hovingh G Kees; Roelants Roosje; Brooks-Wilson Angie; Zwinderman Aeilko H; Smit Andries J; Smelt August H M; Groen Albert K; Hayden Michael R; Kastelein John J P
Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study.
Lancet 2002;359(9300):37-42.
2001: van der Valk M; Kastelein J J; Murphy R L; van Leth F; Katlama C; Horban A; Glesby M; Behrens G; Clotet B; Stellato R K; Molhuizen H O; Reiss P;
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
AIDS (London, England) 2001;15(18):2407-14.
2001: Agema W R; Jukema J W; Pimstone S N; Kastelein J J
Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy.
European heart journal 2001;22(22):2058-74.
2001: Clee S M; Loubser O; Collins J; Kastelein J J; Hayden M R
The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease.
Clinical genetics 2001;60(4):293-300.
2001: Smilde T J; van Wissen S; Wollersheim H; Kastelein J J; Stalenhoef A F
Genetic and metabolic factors predicting risk of cardiovascular disease in familial hypercholesterolemia.
The Netherlands journal of medicine 2001;59(4):184-95.
2001: Sijbrands E J; Westendorp R G; Defesche J C; de Meier P H; Smelt A H; Kastelein J J
Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study.
BMJ (Clinical research ed.) 2001;322(7293):1019-23.
2001: van Dam M J; Penn H J; den Hartog F R; Kragten H A; Trip M D; Buirma R J; Kastelein J J;
A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease.
Clinical therapeutics 2001;23(3):467-78.
2001: Clee S M; Zwinderman A H; Engert J C; Zwarts K Y; Molhuizen H O; Roomp K; Jukema J W; van Wijland M; van Dam M; Hudson T J; Brooks-Wilson A; Genest J; Kastelein J J; Hayden M R
Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease.
Circulation 2001;103(9):1198-205.
2001: Boer J M; Feskens E J; Kuivenhoven J A; Schouten E G; Havekes L M; Kastelein J J; Seidell J C; Kromhout D
Parental history of myocardial infarction: lipid traits, gene polymorphisms and lifestyle.
Atherosclerosis 2001;155(1):149-56.
2001: Smilde T J; van Wissen S; Wollersheim H; Trip M D; Kastelein J J; Stalenhoef A F
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
Lancet 2001;357(9256):577-81.
2001: Leus F R; Zwart M; Kastelein J J; Voorbij H A
PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients.
Atherosclerosis 2001;154(3):641-9.
2001: Umans-Eckenhausen M A; Defesche J C; Sijbrands E J; Scheerder R L; Kastelein J J
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands.
Lancet 2001;357(9251):165-8.
2000: Clee S M; Kastelein J J; van Dam M; Marcil M; Roomp K; Zwarts K Y; Collins J A; Roelants R; Tamasawa N; Stulc T; Suda T; Ceska R; Boucher B; Rondeau C; DeSouich C; Brooks-Wilson A; Molhuizen H O; Frohlich J; Genest J; Hayden M R
Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes.
The Journal of clinical investigation 2000;106(10):1263-70.
2000: Davidson M H; Stein E A; Hunninghake D B; Ose L; Dujovne C A; Insull W; Bertolami M; Weiss S R; Kastelein J J; Scott R S; Campodónico S; Escobar I D; Schrott H G; Bays H; Stepanavage M E; Wu M; Tate A C; Melino M R; Kush D; Mercuri M; Mitchel Y B;
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2000;10(5):253-62.
2000: Kastelein J J; Jukema J W; Zwinderman A H; Clee S; van Boven A J; Jansen H; Rabelink T J; Peters R J; Lie K I; Liu G; Bruschke A V; Hayden M R
Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group.
Circulation 2000;102(14):1629-33.
2000: Hoffer M J; Snieder H; Bredie S J; Demacker P N; Kastelein J J; Frants R R; Stalenhoef A F
The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia.
Atherosclerosis 2000;151(2):443-50.
2000: Lansberg P J; Tuzgöl S; van de Ree M A; Defesche J C; Kastelein J J
[Higher prevalence of familial hypercholesterolemia than expected in adult patients of four family practices in Netherlands]
Nederlands tijdschrift voor geneeskunde 2000;144(30):1437-40.
2000: Trip M D; Lansberg P J; de Jongh S; Kastelein J J
[Familial hypercholesterolemia: recognition and prevention of cardiac complications at a young age]
Nederlands tijdschrift voor geneeskunde 2000;144(30):1425-8.
2000: Kastelein J J; Isaacsohn J L; Ose L; Hunninghake D B; Frohlich J; Davidson M H; Habib R; Dujovne C A; Crouse J R; Liu M; Melino M R; O'Grady L; Mercuri M; Mitchel Y B
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
The American journal of cardiology 2000;86(2):221-3.
2000: Jukema J W; Kastelein J J
Tailored therapy to fit individual profiles. Genetics and coronary artery disease.
Annals of the New York Academy of Sciences 2000;902():17-24; discussion 24-6.
2000: Hayden M R; Clee S M; Brooks-Wilson A; Genest J; Attie A; Kastelein J J
Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency.
Current opinion in lipidology 2000;11(2):117-22.
2000: Clee S M; Bissada N; Miao F; Miao L; Marais A D; Henderson H E; Steures P; McManus J; McManus B; LeBoeuf R C; Kastelein J J; Hayden M R
Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis.
Journal of lipid research 2000;41(4):521-31.
2000: Sijbrands E J; Westendorp R G; Paola Lombardi M; Havekes L M; Frants R R; Kastelein J J; Smelt A H
Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia.
Atherosclerosis 2000;149(2):421-5.
2000: Leus F R; Wittekoek M E; Prins J; Kastelein J J; Voorbij H A
Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia.
Atherosclerosis 2000;149(2):371-7.
2000: Lombardi M P; Redeker E J; Defesche J C; Kamerling S W; Trip M D; Mannens M M; Havekes L M; Kastelein J J
Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in The Netherlands.
Clinical genetics 2000;57(2):116-24.
2000: Visseren F L; Lansberg P J; Erkelens D W; Kastelein J J
[Statins: possibly more than just lowering of the lipid level]
Nederlands tijdschrift voor geneeskunde 2000;144(7):316-21.
2000: Ose L; Davidson M H; Stein E A; Kastelein J J; Scott R S; Hunninghake D B; Campodonico S; Insull W; Escobar I D; Schrott H G; Stepanavage M E; Wu M; Tate A C; Melino M R; Mercuri M; Mitchel Y B
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group.
Clinical cardiology 2000;23(1):39-46.
2000: Liu G; Ashbourne Excoffon K J; Wilson J E; McManus B M; Rogers Q R; Miao L; Kastelein J J; Lewis M E; Hayden M R
Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer.
Human gene therapy 2000;11(1):21-32.
1999: Wittekoek M E; Moll E; Pimstone S N; Trip M D; Lansberg P J; Defesche J C; van Doormaal J J; Hayden M R; Kastelein J J
A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(11):2708-13.
1999: Kastelein J J; Ordovas J M; Wittekoek M E; Pimstone S N; Wilson W F; Gagné S E; Larson M G; Schaefer E J; Boer J M; Gerdes C; Hayden M R
Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women.
Clinical genetics 1999;56(4):297-305.
1999: Marcil M; Brooks-Wilson A; Clee S M; Roomp K; Zhang L H; Yu L; Collins J A; van Dam M; Molhuizen H O; Loubster O; Ouellette B F; Sensen C W; Fichter K; Mott S; Denis M; Boucher B; Pimstone S; Genest J; Kastelein J J; Hayden M R
Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux.
Lancet 1999;354(9187):1341-6.
1999: Wittekoek M E; de Groot E; Prins M H; Trip M D; Büller H R; Kastelein J J
Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease.
Atherosclerosis 1999;146(2):271-9.
1999: Yu L; Heere-Ress E; Boucher B; Defesche J C; Kastelein J; Lavoie M A; Genest J
Familial hypercholesterolemia. Acceptor splice site (G-->C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R(Honduras-1) [LDL-R1061(-1) G-->C].
Atherosclerosis 1999;146(1):125-31.
1999: Boer J M; Kuivenhoven J A; Feskens E J; Schouten E G; Havekes L M; Seidell J C; Kastelein J J; Kromhout D
Physical activity modulates the effect of a lipoprotein lipase mutation (D9N) on plasma lipids and lipoproteins.
Clinical genetics 1999;56(2):158-63.
1999: Brooks-Wilson A; Marcil M; Clee S M; Zhang L H; Roomp K; van Dam M; Yu L; Brewer C; Collins J A; Molhuizen H O; Loubser O; Ouelette B F; Fichter K; Ashbourne-Excoffon K J; Sensen C W; Scherer S; Mott S; Denis M; Martindale D; Frohlich J; Morgan K; Koop B; Pimstone S; Kastelein J J; Genest J; Hayden M R
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency.
Nature genetics 1999;22(4):336-45.
1999: Verhaar M C; Wever R M; Kastelein J J; van Loon D; Milstien S; Koomans H A; Rabelink T J
Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial.
Circulation 1999;100(4):335-8.
1999: Verhaar M C; Honing M L; van Dam T; Zwart M; Koomans H A; Kastelein J J; Rabelink T J
Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids.
Cardiovascular research 1999;42(3):752-60.
1999: Gagné S E; Larson M G; Pimstone S N; Schaefer E J; Kastelein J J; Wilson P W; Ordovas J M; Hayden M R
A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study.
Clinical genetics 1999;55(6):450-4.
1999: Umans-Eckenhausen M A; Defesche J C; Scheerder R L; Cliné F; Kastelein J J
[Tracing of patients with familial hypercholesterolemia in the Netherlands]
Nederlands tijdschrift voor geneeskunde 1999;143(22):1157-61.
1999: Wever R; Boer P; Hijmering M; Stroes E; Verhaar M; Kastelein J; Versluis K; Lagerwerf F; van Rijn H; Koomans H; Rabelink T
Nitric oxide production is reduced in patients with chronic renal failure.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(5):1168-72.
1999: Henderson H E; Kastelein J J; Zwinderman A H; Gagné E; Jukema J W; Reymer P W; Groenemeyer B E; Lie K I; Bruschke A V; Hayden M R; Jansen H
Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins.
Journal of lipid research 1999;40(4):735-43.
1998: Defesche J C; Kastelein J J
Molecular epidemiology of familial hypercholesterolaemia.
Lancet 1998;352(9141):1643-4.
1998: Henderson H E; Bijvoet S M; Mannens M A; Bruin T; Erkelens D W; Hayden M R; Kastelein J J
Ile225Thr loop mutation in the lipoprotein lipase (LPL) gene is a de novo event.
American journal of medical genetics 1998;78(4):313-6.
1998: Prins J; van der Hoek Y Y; Biesheuvel T H; Leus F R; van Rijn H J; Kastelein J J
The functional and clinical significance of the Met-->Thr substitution in Kringle IV type 10 of apolipoprotein(a).
Thrombosis research 1998;90(3):125-30.
1998: Hoffer M J; Bredie S J; Snieder H; Reymer P W; Demacker P N; Havekes L M; Boomsma D I; Stalenhoef A F; Frants R R; Kastelein J J
Gender-related association between the -93T-->G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia.
Atherosclerosis 1998;138(1):91-9.
1998: Diekman T; Demacker P N; Kastelein J J; Stalenhoef A F; Wiersinga W M
Increased oxidizability of low-density lipoproteins in hypothyroidism.
The Journal of clinical endocrinology and metabolism 1998;83(5):1752-5.
1998: Wittekoek M E; Pimstone S N; Reymer P W; Feuth L; Botma G J; Defesche J C; Prins M; Hayden M R; Kastelein J J
A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia.
Circulation 1998;97(8):729-35.
1998: Kastelein J J; Groenemeyer B E; Hallman D M; Henderson H; Reymer P W; Gagné S E; Jansen H; Seidell J C; Kromhout D; Jukema J W; Bruschke A V; Boerwinkle E; Hayden M R
The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group.
Clinical genetics 1998;53(1):27-33.
1998: Verhaar M C; Wever R M; Kastelein J J; van Dam T; Koomans H A; Rabelink T J
5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia.
Circulation 1998;97(3):237-41.
1998: Kuivenhoven J A; Jukema J W; Zwinderman A H; de Knijff P; McPherson R; Bruschke A V; Lie K I; Kastelein J J
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
The New England journal of medicine 1998;338(2):86-93.
1997: Ehrenborg E; Clee S M; Pimstone S N; Reymer P W; Benlian P; Hoogendijk C F; Davis H J; Bissada N; Miao L; Gagné S E; Greenberg L J; Henry R; Henderson H; Ordovas J M; Schaefer E J; Kastelein J J; Kotze M J; Hayden M R
Ethnic variation and in vivo effects of the -93t-->g promoter variant in the lipoprotein lipase gene.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(11):2672-8.
1997: Lombardi P; Defesche J C; Kamerling S W; Kastelein J J; Havekes L M
A novel mutation M-21V in exon 1 of the low density lipoprotein receptor gene causing familial hypercholesterolemia.
Clinical genetics 1997;51(6):430-1.
1997: Groenemeijer B E; Hallman M D; Reymer P W; Gagné E; Kuivenhoven J A; Bruin T; Jansen H; Lie K I; Bruschke A V; Boerwinkle E; Hayden M R; Kastelein J J
Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group.
Circulation 1997;95(12):2628-35.
1997: Prins J; Leus F R; van der Hoek Y Y; Kastelein J J; Bouma B N; van Rijn H J
The identification and significance of a Thr-->Pro polymorphism in kringle IV type 8 of apolipoprotein(a).
Thrombosis and haemostasis 1997;77(5):949-54.
1997: Pimstone S N; Defesche J C; Clee S M; Bakker H D; Hayden M R; Kastelein J J
Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(5):826-33.
1997: van der Hoek Y Y; Lingenhel A; Kraft H G; Defesche J C; Kastelein J J; Utermann G
Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective ApoB.
The Journal of clinical investigation 1997;99(9):2269-73.
1997: Lombardi P; Defesche J C; Kamerling S W; Kastelein J J; Havekes L M
A novel V415A mutation in exon 9 of the low density lipoprotein receptor gene causing familial hypercholesterolemia.
Clinical genetics 1997;51(4):286-7.
1997: Kuivenhoven J A; Groenemeyer B E; Boer J M; Reymer P W; Berghuis R; Bruin T; Jansen H; Seidell J C; Kastelein J J
Ser447stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(3):595-9.
1997: Kuivenhoven J A; de Knijff P; Boer J M; Smalheer H A; Botma G J; Seidell J C; Kastelein J J; Pritchard P H
Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(3):560-8.
1997: Kuivenhoven J A; Pritchard H; Hill J; Frohlich J; Assmann G; Kastelein J
The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.
Journal of lipid research 1997;38(2):191-205.
1997: de Maat M P; Knipscheer H C; Kastelein J J; Kluft C
Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
Thrombosis and haemostasis 1997;77(1):75-9.
1997: Stroes E; Kastelein J; Cosentino F; Erkelens W; Wever R; Koomans H; Lüscher T; Rabelink T
Tetrahydrobiopterin restores endothelial function in hypercholesterolemia.
The Journal of clinical investigation 1997;99(1):41-6.
1997: Foubert L; Bruin T; De Gennes J L; Ehrenborg E; Furioli J; Kastelein J; Benlian P; Hayden M
A single Ser259Arg mutation in the gene for lipoprotein lipase causes chylomicronemia in Moroccans of Berber ancestry.
Human mutation 1997;10(3):179-85.
1997: Knipscheer H C; Kindt I; van den Ende A; Nurmohamed M T; Smalbraak H; Mulder W J; Kastelein J J
Magnesium pyridoxal-5'-phosphate glutamate, "A vitamin B6 derivative", does not affect lipoprotein levels in patients with familial hypercholesterolaemia.
European journal of clinical pharmacology 1997;51(6):499-503.
1996: Lombardi P; Kamerling S W; Defesche J C; Kastelein J J; Havekes L M
Identification of a double mutation in the low-density lipoprotein receptor gene causing familial hypercholesterolemia.
Clinical genetics 1996;50(6):525-6.
1996: Bijvoet S M; Wiebusch H; Ma Y; Reymer P W; Bruin T; Bakker H D; Funke H; Assmann G; Hayden M R; Kastelein J J
Compound heterozygosity for a known and a novel defect in the lipoprotein lipase gene (Asp250-->Asn; Ser251-->Cys) resulting in lipoprotein lipase (LPL) deficiency.
The Netherlands journal of medicine 1996;49(5):189-95.
1996: Jukema J W; van Boven A J; Groenemeijer B; Zwinderman A H; Reiber J H; Bruschke A V; Henneman J A; Molhoek G P; Bruin T; Jansen H; Gagné E; Hayden M R; Kastelein J J
The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
Circulation 1996;94(8):1913-8.
1996: Kuivenhoven J A; Weibusch H; Pritchard P H; Funke H; Benne R; Assmann G; Kastelein J J
An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease).
The Journal of clinical investigation 1996;98(2):358-64.
1996: Knipscheer H C; Boelen C C; Kastelein J J; van Diermen D E; Groenemeijer B E; van den Ende A; Büller H R; Bakker H D
Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia.
Pediatric research 1996;39(5):867-71.
1996: Bijvoet S; Gagné S E; Moorjani S; Gagné C; Henderson H E; Fruchart J C; Dallongeville J; Alaupovic P; Prins M; Kastelein J J; Hayden M R
Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in heterozygotes for lipoprotein lipase deficiency.
Journal of lipid research 1996;37(3):640-50.
1996: Kuivenhoven J A; Stalenhoef A F; Hill J S; Demacker P N; Errami A; Kastelein J J; Pritchard P H
Two novel molecular defects in the LCAT gene are associated with fish eye disease.
Arteriosclerosis, thrombosis, and vascular biology 1996;16(2):294-303.
1996: Wiebusch H; Funke H; Bruin T; Bucher H; von Eckardstein A; Kastelein J J; Assmann G
Compound heterozygosity for a known (D250N) and a novel (E410K) missense mutation in the C-terminal domain of lipoprotein lipase causes familial chylomicronemia.
Human mutation 1996;8(4):381-3.
1996: van den Ende A; van der Hoek Y Y; Kastelein J J; Koschinsky M L; Labeur C; Rosseneu M
Lipoprotein [a].
Advances in clinical chemistry 1996;32():73-134.
1995: Kuivenhoven J A; van Voorst tot Voorst E J; Wiebusch H; Marcovina S M; Funke H; Assmann G; Pritchard P H; Kastelein J J
A unique genetic and biochemical presentation of fish-eye disease.
The Journal of clinical investigation 1995;96(6):2783-91.
1995: Pimstone S N; Gagné S E; Gagné C; Lupien P J; Gaudet D; Williams R R; Kotze M; Reymer P W; Defesche J C; Kastelein J J
Mutations in the gene for lipoprotein lipase. A cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(10):1704-12.
1995: Zhang H; Reymer P W; Liu M S; Forsythe I J; Groenemeyer B E; Frohlich J; Brunzell J D; Kastelein J J; Hayden M R; Ma Y
Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291-->Ser mutation in the human LPL gene.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(10):1695-703.
1995: Lansberg P J; Mitchel Y B; Shapiro D; Kastelein J J; Altman R; Jerums G; Bolzano K; Giannini S; Davignon J; DeWailly P
Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients.
Atherosclerosis 1995;116(2):153-62.
1995: Reymer P W; Groenemeyer B E; van de Burg R; Kastelein J J
Apolipoprotein E genotyping on agarose gels.
Clinical chemistry 1995;41(7):1046-7.
1995: Reymer P W; Gagné E; Groenemeyer B E; Zhang H; Forsyth I; Jansen H; Seidell J C; Kromhout D; Lie K E; Kastelein J
A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis.
Nature genetics 1995;10(1):28-34.
1995: Lombardi P; Sijbrands E J; van de Giessen K; Smelt A H; Kastelein J J; Frants R R; Havekes L M
Mutations in the low density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing.
Journal of lipid research 1995;36(4):860-7.
1994: van der Hoek Y Y; Sangrar W; Côté G P; Kastelein J J; Koschinsky M L
Binding of recombinant apolipoprotein(a) to extracellular matrix proteins.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1994;14(11):1792-8.
1994: Knipscheer H C; Nurmohamed M T; Van den Ende A; Plaat B; Pruijs H J; Mulder W J; Kastelein J J
Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.
Journal of internal medicine 1994;236(4):377-84.
1994: Tuzgöl S; Bijvoet S M; Bruin T; Kastelein J J; Hayden M R
Apolipoprotein CII-Padova (Tyr37-->stop) as a cause of chylomicronaemia in an Italian kindred from Siculiana.
Journal of medical genetics 1994;31(8):622-6.
1994: Bruin T; Groot N B; Jansen J; Kastelein J J
The C-terminus of lipoprotein lipase is essential for biological function but contains no domain for glycosylphosphatidylinositol anchoring.
European journal of biochemistry / FEBS 1994;221(3):1019-25.
1994: Van den Broek A J; Hollaar L; Schaefer H I; Van der Laarse A; Schuster H; Defesche J C; Kastelein J J; Van 't Hooft F M
Screening for familial defective apolipoprotein B-100 with improved U937 monocyte proliferation assay.
Clinical chemistry 1994;40(3):395-9.
1994: Bijvoet S M; Bruin T; Tuzgöl S; Bakker H D; Hayden M R; Kastelein J J
Homozygosity for a mutation in the lipoprotein lipase gene (Gly139-->Ser) causes chylomicronaemia in a boy of Spanish descent.
Human genetics 1994;93(3):339-43.
1994: van der Hoek Y Y; Kastelein J J; Koschinsky M L
Analysis of structure--function relationships in human apolipoprotein(a).
Canadian journal of physiology and pharmacology 1994;72(3):304-10.
1994: Bruin T; Tuzgöl S; Mulder W J; van den Ende A E; Jansen H; Hayden M R; Kastelein J J
A compound heterozygote for lipoprotein lipase deficiency, Val69-->Leu and Gly188-->Glu: correlation between in vitro LPL activity and clinical expression.
Journal of lipid research 1994;35(3):438-45.
1993: Bruin T; Tuzgöl S; van Diermen D E; Hoogerbrugge-van der Linden N; Brunzell J D; Hayden M R; Kastelein J J
Recurrent pancreatitis and chylomicronemia in an extended Dutch kindred is caused by a Gly154-->Ser substitution in lipoprotein lipase.
Journal of lipid research 1993;34(12):2109-19.
1993: Defesche J C; van Diermen D E; Lansberg P J; Lamping R J; Reymer P W; Hayden M R; Kastelein J J
South African founder mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia in the Dutch population.
Human genetics 1993;92(6):567-70.
1993: Defesche J C; Pricker K L; Hayden M R; van der Ende B E; Kastelein J J
Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia.
Archives of internal medicine 1993;153(20):2349-56.
1993: Henderson H E; Ma Y; Liu M S; Clark-Lewis I; Maeder D L; Kastelein J J; Brunzell J D; Hayden M R
Structure-function relationships of lipoprotein lipase: mutation analysis and mutagenesis of the loop region.
Journal of lipid research 1993;34(9):1593-602.
1993: Hayden M R; Kastelein J J; Funke H; Brunzell J D; Ma Y
Phenotypic variation of mutations in the human lipoprotein-lipase gene.
Biochemical Society transactions 1993;21(2):506-9.
1993: van der Hoek Y Y; Wittekoek M E; Beisiegel U; Kastelein J J; Koschinsky M L
The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms.
Human molecular genetics 1993;2(4):361-6.
1993: Defesche J C; Lansberg P J; Reymer P W; Lamping R J; Kastelein J J
Analysis of the Afrikaner mutation in exon 9 of the low-density lipoprotein receptor gene in a large Dutch kindred suffering from familial hypercholesterolaemia.
The Netherlands journal of medicine 1993;42(1-2):53-60.
1993: Bijvoet S M; Bruin T; Kastelein J J
The familial hyperchylomicronaemia syndrome.
The Netherlands journal of medicine 1993;42(1-2):36-44.
1992: Defesche J C; van de Ree M A; Kastelein J J; van Diermen D E; Janssens N W; van Doormaal J J; Hayden M R
Detection of the Pro664-Leu mutation in the low-density lipoprotein receptor and its relation to lipoprotein(a) levels in patients with familial hypercholesterolemia of Dutch ancestry from The Netherlands and Canada.
Clinical genetics 1992;42(6):273-80.
1992: Bruin T; Kastelein J J; Van Diermen D E; Ma Y; Henderson H E; Stuyt P M; Stalenhoef A F; Sturk A; Brunzell J D; Hayden M R
A missense mutation Pro157 Arg in lipoprotein lipase (LPLNijmegen) resulting in loss of catalytic activity.
European journal of biochemistry / FEBS 1992;208(2):267-72.
1992: Ma Y; Wilson B I; Bijvoet S; Henderson H E; Cramb E; Roederer G; Ven Murthy M R; Julien P; Bakker H D; Kastelein J J
A missense mutation (Asp250----Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries.
Genomics 1992;13(3):649-53.
1992: Dekker E; Büller H R; Kastelein J J
[Postmenopausal estrogen substitution and the risk of atherosclerotic heart and vascular diseases]
Nederlands tijdschrift voor geneeskunde 1992;136(25):1197-200.
1992: Kastelein J J; Pritchard P H; Erkelens D W; Kuivenhoven J A; Albers J J; Frohlich J J
Familial high-density-lipoprotein deficiency causing corneal opacities (fish eye disease) in a family of Dutch descent.
Journal of internal medicine 1992;231(4):413-9.
1992: Lansberg P J; Kastelein J J; Defesche J C; ten Cate J W
[The treatment of familial hypercholesterolemia]
Nederlands tijdschrift voor geneeskunde 1992;136(15):734-8.
1992: Kastelein J J; Bruin T; ten Cate J W
[Lipoprotein lipase]
Nederlands tijdschrift voor geneeskunde 1992;136(15):727-30.
1992: Ma Y H; Bruin T; Tuzgol S; Wilson B I; Roederer G; Liu M S; Davignon J; Kastelein J J; Brunzell J D; Hayden M R
Two naturally occurring mutations at the first and second bases of codon aspartic acid 156 in the proposed catalytic triad of human lipoprotein lipase. In vivo evidence that aspartic acid 156 is essential for catalysis.
The Journal of biological chemistry 1992;267(3):1918-23.
1991: Bruin T; Reymer P W; Groenemeyer B E; Talmud P J; Kastelein J J
HindIII-polymorphism in the LPL-gene detected by PCR.
Nucleic acids research 1991;19(22):6346.
1991: Funke H; von Eckardstein A; Pritchard P H; Albers J J; Kastelein J J; Droste C; Assmann G
A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(11):4855-9.
1991: Gorter J W; Schilte P P; Lansberg P J; Kastelein J J; Bakker H D
[A patient with the homozygote form of familial hypercholesterolemia]
Tijdschrift voor kindergeneeskunde 1991;59(3):88-91.
1991: Bakker H D; Bruin T; Schaap M C; Lansberg P J; Kastelein J J
The prediction of the therapeutic response to cholesterol lowering drugs in an 11-year-old boy with homozygous familial hypercholesterolaemia.
Journal of inherited metabolic disease 1991;14(3):389-92.
1990: Monsalve M V; Henderson H; Roederer G; Julien P; Deeb S; Kastelein J J; Peritz L; Devlin R; Bruin T; Murthy M R
A missense mutation at codon 188 of the human lipoprotein lipase gene is a frequent cause of lipoprotein lipase deficiency in persons of different ancestries.
The Journal of clinical investigation 1990;86(3):728-34.
1990: Kastelein J J; Haines J L; Hayden M R
The gene causing familial hypoalphalipoproteinemia is not caused by a defect in the apo AI-CIII-AIV gene cluster in a Spanish family.
Human genetics 1990;84(5):396-400.
1989: Langlois S; Deeb S; Brunzell J D; Kastelein J J; Hayden M R
A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(3):948-52.
1988: Langlois S; Kastelein J J; Hayden M R
Characterization of six partial deletions in the low-density-lipoprotein (LDL) receptor gene causing familial hypercholesterolemia (FH).
American journal of human genetics 1988;43(1):60-8.
1988: Hayden M R; Hewitt J; Wasmuth J J; Kastelein J J; Langlois S; Conneally M; Haines J; Smith B; Hilbert C; Allard D
A polymorphic DNA marker that represents a conserved expressed sequence in the region of the Huntington disease gene.
American journal of human genetics 1988;42(1):125-31.
1985: Beyer C; Statius van Eps L W; Kastelein J J; Brandjes D P; Mairuhu W M; van den Ende A
Urinary creatine: biochemical indicator for evaluation of sickle cell crises.
Clinical chemistry 1985;31(7):1232-4.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

John Kastelein

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Physiology

Procedures

Geographic Areas

Living Beings

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of John Kastelein (preview)

All Publications